白念珠菌对唑类抗真菌药物分子耐药机制的研究进展
被引量:1
摘要
由于唑类抗真菌药物在临床的长期广泛应用,白念珠菌对唑类药物发生耐药的现象逐渐增多,对唑类药物耐药机制的研究成为目前研究的重点。本文综述了白念珠菌对唑类药物的分子耐药机制主要有编码药物靶酶基因的表达增强或突变、编码药物流出泵基因的过度表达、生物膜的形成等。
出处
《中国麻风皮肤病杂志》
2010年第5期342-344,共3页
China Journal of Leprosy and Skin Diseases
参考文献17
-
1Paulitsch A,Weger W,Ginter-Hanselmayer G,et al.A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz,Austria.Mycoses 2006;49(6):471-475.
-
2Lamb DC,Kelly DE,Schunck WH,et al.The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity.J Bio Chem 1997;272(9):5682-5688.
-
3Chau AS,Mendrick CA,Sabatelli FJ,et al.Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.Antimicro Agents Chemother 2004; 48(6):2124-2131.
-
4Perea S,Lopez-Ribot JL,Kirkpatrick WR,et al.Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.Antimicro Agents Chemother 2001;45(10):2676-2684.
-
5White TC,Holleman S,Dy F,et al.Resistance mechanisms in clinical isolates of Candida albicans.Antimicro Agents Chemother 2002;46(6):1704-1713.
-
6Cernicka J,Subik J.Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis.Int J Antimicrob Agents 2006;27(5):403-408.
-
7Xu Y,Chen L,Li C.Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations.J Antimic Chem 2008;61(4):798-804.
-
8Sanglard D,Ischer F,Parkinson T,et al.Candida albicans mutations in the ergosterol biosynthetic pathway andresistance to several antifungal agents.Antimicrob Agents Chemother 2003;47:2404-2412.
-
9郭慧君,夏忠弟.白色念珠菌耐药蛋白(Cdr1p)表达及调控机制研究进展[J].国外医药(抗生素分册),2005,26(6):244-247. 被引量:2
-
10Marr KA,Lyons CN,Ha K,et al.Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.Antimicrob Agents Chemother 2001;45(1):52-59.
二级参考文献26
-
1White TC, Holle .man S, Dy F, et al. Resistance mechanisms in clinical isolates of Candida albicans [ J ]. Antimictob Agents Chemother ,2002,46( 6 ): 1704.
-
2Prasad R, De WP, Goffeau A, et al. Molecular cloning and characterization of a novel gene of Candida albicans, cdr1,conferring multiple resistance to drugs and antifungals [ J ].Curr Genet, 1995,27:320.
-
3Sauna ZE, Ambudkar SV. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affct different functional outcomes [ J ]. J Biol Chem,2001,276:11653.
-
4Diederichs K, Dicz J, Greller G, et al. Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archacon Thermocopccus litoralis [ J ]. EMBO J,2000 ,19 :5951.
-
5Decottignies A, Goffeau A. Complete inventory of the yeast ABC proteins [ J ]. Nat Genet, 1997,15:137.
-
6Jha S, Karnani N, Dhar SK, et al. Purification and characterization of the N-terminal nucleotide binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of WalkerA is critical for ATP hydrolysis [ J ]. Biochemistry,2003,42:10822.
-
7Jha S, Karnani N, Lynn AM, et al. Covalent modification of cysteine 193 impairs ATPase function of nucleotide-binding domain of a Candida drug efflux pump [ J ]. Biochem Biophys Res Commun,2003 ,310 :869.
-
8Sudhakar J, Neelam D, Neerja K, et al. ABC multidrug transporter Cdr1 p of Candida albicans has divergent nucleotide-binding domains which display functional asymmetry [J]. FEMS Yeast Research ,2004,5:63.
-
9Maesaki S, Marichal P, Bossche HV, et al. Rhodamine 6G efflux for the detection of cdr1 -overexpressing azole-resistant Candida albicans strains [ J ]. J Antimicrob Chemother ,1999,44:27.
-
10Dogra S, Krishnamurthy S, Gupta V, et al. Asymmetric distribution of phosphatidy-lethanolamine in C. albicans: possible mediation by cdr1, a multidrug transporter belonging to ATP binding cassette ( ABC ) superfamily [ J ]. Yeat,1999,15:111.
同被引文献11
-
1曹先伟,冀朝辉,李若瑜,付颖媛,王端礼.白色念珠菌对唑类抗真菌药物的耐药机制探讨[J].中华医院感染学杂志,2007,17(3):258-262. 被引量:18
-
2Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infec- tions[J]. Lancet Infect Dis,2011,11(2) :142-151.
-
3Pfaller MA. Diekema DJ. Epidemiology of invasive candidiasis:a persistent public health problem[ J]. ClinMicrobiol Rev, 2007 , 20( 1 ) :133-163.
-
4Cabral ME, Figueroa LI, Farina JI. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae and Candida utilis-bioassays and ergosterol quantifica- tion [ J ]. Rev Iberoam Micol, 2013,30 ( 1 ) :31-38.
-
5Menezes EA,VasconeelosJOnior AA,Silva CL,et al. In vitro syn- ergism of simvastatin and fluconazole against Candida species [ J ]. Rev Inst Med Trop Sao Paulo,2012 ,54 (4) : 197-199.
-
6Bink A, Kucharikovd S, Neirinek B, et al. The nonsteroidal an- tiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms [ J ]. Infect Dis, 2012,206( 11 ) :1790-1797.
-
7Argenta JS, Alves SH, Silveira F, et al. In vitro and in vivo sus- ceptibility of two-drug and three-drug combinations of terbin- afine, itraconazole, caspofungin, ibuprofen and fluvastatin a- gainst Pythiuminsidiosum [ J ]. Vet Microbiol, 2012,157 ( 1-2 ) : 137-142.
-
8Kofla G, Turner V, Schulz B, et al. Doxorubicin induces drug ef- flux pumps in Candida albicans [J]. Med Mycol,2011,49(2) : 132-142.
-
9Zhai B, Wu C,Wang L, et al. The antidepressant sertraline pro- vides a promising therapeutic option for neurotropic Cryptococcal infections [ J ]. Antimicrob Agents Chemother, 2012,56 ( 7 ) : 3758 -3766.
-
10Shinde RB, Chauhan NM, Raut JS, et al. Sensitization of Candida albicans biofilms to various antifungal drugs by cyclos- porine A [ J ]. Ann ClinMicrobiolAntimicrob, 2012,11:27.
二级引证文献6
-
1袁公,王玉连,安毛毛,卢祥婷,吴建华.利福喷丁联合氟康唑对耐药白念珠菌感染小鼠的作用及免疫机制分析[J].中国药师,2019,22(1):20-25. 被引量:5
-
2吴真珍,骆志成.抗真菌药物增效剂对白色念珠菌生物膜的作用[J].甘肃医药,2015,34(5):337-339.
-
3王玉连,张璐璐,秦玉璘,曹永兵,吴建华.利福喷丁对氟康唑体外抗耐药白念珠菌的增效作用[J].中国真菌学杂志,2016,11(3):156-159. 被引量:4
-
4柏长青,王喜阳,王绿洋,闫佳星,李照亮,练计明,张宛玥,胡焕焕,姬国杰.7种甲沟炎常见外用药物抑菌效果比较[J].河南医学研究,2017,26(22):4052-4054. 被引量:5
-
5王莉,王华,周洁,翟晓翔.他克莫司与常用抗真菌药体外协同抗白念珠菌作用的初探[J].中国真菌学杂志,2021,16(4):257-261.
-
6马超,钟叙春,张荣山.苦参碱与氟康唑联用对白色念珠菌的抗菌活性研究[J].常州实用医学,2022,38(1):4-6.
-
1陶传敏,李萍,吕晓菊.常见革兰氏阴性杆菌对氟喹诺酮类抗菌药的分子耐药机制[J].国外医药(抗生素分册),2004,25(2):76-78. 被引量:4
-
2夏宁,胡成平.表皮生长因子受体-酪氨酸激酶抑制剂分子耐药机制研究[J].世界临床药物,2012,33(4):202-205. 被引量:1
-
3谷蕴婷,黄海荣.结核分枝杆菌对吡嗪酰胺耐药相关研究进展[J].中华结核和呼吸杂志,2016,39(10):814-817. 被引量:7
-
4Foote SJ,Cowman AF,杨彬.抗疟药的作用方式和抗药性产生机制[J].国外医学(寄生虫病分册),1994,21(5):200-204.
-
5吕晓菊.临床重要的β-内酰胺酶及其研究进展[J].四川生理科学杂志,2003,25(3):116-117.
-
6陈寒冬,钟利.金黄色葡萄球菌对氟喹诺酮类药物耐药机制的研究进展[J].国外医药(抗生素分册),2009,30(1):9-12. 被引量:3
-
7王重振,钱利生.细菌对喹诺酮类抗菌药的分子耐药机制[J].中国生物工程杂志,2003,23(12):26-30. 被引量:13
-
8敖俊红,廖勇,郝震锋,祝贺,杨蓉娅.烟曲霉伊曲康唑耐药株的体外诱导及与CYP51A基因相关性研究[J].实用皮肤病学杂志,2014,7(4):253-255. 被引量:1
-
9王英,顾军.念珠菌病耐药性的分子机制研究进展[J].中国麻风皮肤病杂志,2003,19(5):469-470. 被引量:1
-
10梁蓓蓓,李悦,牛卉,王睿,王瑾.研究产KPC肺炎克雷伯菌的相关文献计量分析[J].中国临床药理学杂志,2014,30(7):635-638.